This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cuneo, K. C. Articles by Willey, C. D. Search for Related Content PubMed Articles by Cuneo, K. C. Articles by Willey, C. D.

HIV Protease Inhibitors Enhance the Efficacy of Irradiation

¹ Vanderbilt University School of Medicine; Departments of ² Radiation Oncology and ³ Cancer Biology, Vanderbilt University, Nashville, Tennessee

Requests for reprints: Christopher D. Willey, Department of Radiation Oncology, The Vanderbilt Clinic, 1301 22nd Avenue, South B-902, Nashville, TN 37232-5671. Phone: 615-322-2555; Fax: 615-343-6589; E-mail: christopher.willey{at}vanderbilt.edu.

Tumor vascular endothelium is rather resistant to the cytotoxic effects of radiation. The HIV protease inhibitors (HPI) amprenavir, nelfinavir, and saquinavir have previously been shown to sensitize tumor cells to the cytotoxic effects of radiation. Additionally, this class of drug has been shown to inhibit angiogenesis and tumor cell migration. Therefore, in the current study, we wanted to determine whether HPIs could enhance the effect of radiation on endothelial function. Our study shows that HPIs, particularly nelfinavir, significantly enhance radiations effect on human umbilical vein endothelial cells (HUVEC) and tumor vascular endothelium. We show that pretreatment of HUVEC with nelfinavir results in enhanced cytotoxicity, including increased apoptosis, when combined with radiation. Moreover, using several functional assays, we show that combination treatment effectively blocks endothelial cell migration and organization. These findings were accompanied by attenuation of Akt phosphorylation, a known pathway for radioresistance. Last, in vivo analysis of tumor microvasculature destruction showed a more than additive effect for nelfinavir and radiation. This study shows that HPIs can enhance the effect of ionizing radiation on vascular endothelium. Therefore, the Food and Drug Administration–approved drug, nelfinavir, may be an effective radiosensitizer in the clinic. [Cancer Res 2007;67(10):4886–93]

This article has been cited by other articles:

				D. Maksimovic-Ivanic, S. Mijatovic, D. Miljkovic, L. Harhaji-Trajkovic, G. Timotijevic, M. Mojic, D. Dabideen, K. F. Cheng, J. A. McCubrey, K. Mangano, et al. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt Mol. Cancer Ther., May 1, 2009; 8(5): 1169 - 1178. [Abstract] [Full Text] [PDF]

				T. B. Brunner, M. Geiger, G. G. Grabenbauer, M. Lang-Welzenbach, T. S. Mantoni, A. Cavallaro, R. Sauer, W. Hohenberger, and W. G. McKenna Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer J. Clin. Oncol., June 1, 2008; 26(16): 2699 - 2706. [Abstract] [Full Text] [PDF]

				T. Tu, D. Thotala, L. Geng, D. E. Hallahan, and C. D. Willey Bone Marrow X Kinase-Mediated Signal Transduction in Irradiated Vascular Endothelium Cancer Res., April 15, 2008; 68(8): 2861 - 2869. [Abstract] [Full Text] [PDF]